BridgeMD
A Study to Assess the Adverse Events and Change in Disease Activity of Atogepant Oral Tablets in Pediatric Participants with Chronic Migraine
EU CTIS ID: 2024-513836-28-00
What this study is testing
The primary objective is to evaluate the safety and efficacy of atogepant when administered daily for the preventive treatment of chronic migraine in pediatric subjects 12 to 17 years of age.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Weight is ≥ 20 kg (44 pounds) and < 135 kg (298 pounds).
- Subject has a history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3) (2018) for at least 6 months as of Visit 1.
- Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the treatment of migraine.
You likely can't join if
- Migraine with brainstem aura, hemiplegic migraine, or retinal migraine as defined by ICHD-3 (2018).
- Current diagnosis of new daily persistent headache, trigeminal autonomic cephalgia (e.g., cluster headache), or painful cranial neuropathy as defined by ICHD-3 (2018).
The study team makes the final eligibility decision.
Where it's taking place
- Puerto Rico
- Japan
- United Kingdom
- Canada
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Puerto Rico; Japan; United Kingdom; Canada; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.